Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
The innovation-powered content management platform to produce and distribute high quality digital content
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
When faced with life-or-death treatment decisions, healthcare stakeholders need more than clinical data alone — they need a complete picture of both effectiveness and value. Health Economics and Outcomes Research (HEOR) delivers this by uncovering the true impact of therapies on patient outcomes, healthcare costs, and quality of life. For the pharmaceutical industry, HEOR isn’t just an analytical tool, it’s a strategic necessity, shaping decisions that determine market access, pricing, and long-term success in an increasingly evidence-driven industry.
Health Economics and Outcomes Research (HEOR) is a critical field within the life sciences industry, focusing on generating evidence to demonstrate the value of healthcare interventions, including drugs, devices, and services.
It combines economic evaluations and outcomes research to assess the clinical, economic, and humanistic impact of interventions on patients and healthcare systems.
With budget constraints tightening and drug prices facing greater scrutiny, Health Economics and Outcomes Research has become a cornerstone of modern pharmaceutical strategy. Policymakers increasingly rely on HEOR insights to guide funding decisions, which directly influence both drug pricing and access to therapies. And as precision medicine and value-based care continue to gain traction, the need for reliable HEOR data will only grow, shaping how treatments are developed, marketed, and delivered to patients.
HEOR plays several pivotal roles in helping pharma companies and healthcare stakeholders make better, evidence-based decisions.
Source: https://www.ispor.org/heor-explained
Pharmaceutical companies are expected to go beyond simply proving that their treatments work — they need to show that their products provide real, measurable benefits for both patients and healthcare systems. HEOR steps in by combining data from clinical trials, real-world outcomes, and patient-reported quality of life. This all-encompassing approach enables companies to clearly demonstrate the cost-effectiveness and long-term impact of their therapies, giving healthcare payers, regulators, and healthcare providers the confidence to support their use.
Getting a new drug to market isn’t just about approval, it’s about making sure payers are willing to reimburse for it. Health Economics and Outcomes Research data is crucial here. It helps pharma companies show how their product stacks up against alternatives — both in terms of clinical outcomes and economic value. In a crowded market, strong HEOR evidence can make the difference between a successful launch and struggling to gain traction.
HEOR also plays a key role in the choices healthcare providers make every day. By shedding light on the economic aspects of treatment options, HEOR helps providers identify which therapies offer the best balance of effectiveness and affordability. This ultimately leads to better prescribing practices, positive health outcomes for patients, and smarter use of healthcare resources.
Health Economics and Outcomes Research is vital within the operational frameworks of pharmaceutical companies, because it helps connect the dots between a drug’s effectiveness in clinical trials and its value in the real world.
The development of a new product is an immensely costly and time-consuming process — it sometimes takes about 10 to 15 years to finish all clinical trials, get approval, and launch the drug. Since the stakes are so high, pharmaceutical manufacturers need to be sure that the investment made will bring profits.
That’s why, generally, pharma companies embed HEOR teams into the development process as early as Phase II clinical trials. It’s important to note, though, that while Phase II remains standard, some scenarios warrant even preclinical or Phase I HEOR engagement.
The early integration of HEOR guides the pharmaceutical industry in making informed decisions about which products to advance through the development pipeline.
Just from the information above, you can understand the value HEOR experts bring, but let’s discuss this further.
HEOR experts develop sophisticated cost-effectiveness models that guide critical pricing strategies. They analyze information from clinical trials and real-world use to answer crucial questions about the new therapy. Armed with the data, pharma companies can negotiate better deals with payers and justify pricing by proving the drug’s long-term value.
As we’ve mentioned, the healthcare is moving towards value-based care — which is certainly a step in the right direction. And patients are at the heart of it. So it’s no longer enough for new drugs to meet clinical endpoints alone.
HEOR specialists, therefore, dig deep into patient-reported outcomes (PROs) and quality-of-life measures to understand how therapies impact daily life for patients. When pharma companies incorporate these insights into their drug development, they can create treatments that align with the needs, expectations, and preferences of their end customers. This approach not only improves patient engagement but also increases the likelihood of positive adoption and long-term adherence to therapy.
In markets where multiple treatments compete for attention, it’s not just important to stand out, it’s pretty much out of the question. This is where HEOR insights are indispensable. By showcasing how a drug saves healthcare costs, improves patient outcomes, or reduces side effects, HEOR teams help pharmaceutical companies build a compelling case for their product. It’s about positioning the drug as the best option — not just clinically, but economically and practically — which can make all the difference in gaining market share.
Health Economics and Outcomes Research covers a variety of study types, each designed to assess the clinical and economic impact of healthcare interventions. These studies provide key insights to pharmaceutical companies, payers, and government agencies, helping them make smart healthcare decisions on pricing, reimbursement, and resource allocation.
Here are the various types of HEOR studies:
Let’s break down the unique contributions that each of these studies bring to the table.
CEA compares the costs and outcomes of different treatments to figure out which one delivers the best results for the money spent. It’s all about finding the most efficient way to allocate resources — think of it as a way to measure the “bang for your buck” in healthcare.
CUA builds on CEA by factoring in both the quantity and quality of life improvements from a treatment, using the quality-adjusted life years metric. This makes it possible to compare very different health interventions on a level playing field.
BIA looks at how adopting a new treatment will affect a healthcare budget. It’s a crucial tool for understanding whether a new therapy is financially viable, giving stakeholders a clear picture of the short- and long-term costs associated with the intervention.
When two or more treatments are expected to deliver the same clinical outcomes, CMA helps by focusing solely on the costs. It’s a straightforward way to see which option is more budget-friendly without worrying about differences in effectiveness.
These studies dig into real-world data from existing healthcare databases to uncover patterns in treatment use, costs, and outcomes. They’re great for seeing how therapies perform in everyday clinical settings, beyond the controlled world of clinical trials.
While primarily clinical studies, RCTs can also be part of HEOR when they include economic evaluations alongside clinical outcomes. They are considered the gold standard for assessing efficacy and safety.
These studies observe treatment outcomes in real-world environments without altering or assigning treatments. Cohort studies, case-control studies, and cross-sectional studies are common types that provide data on effectiveness and safety in diverse populations.
Systematic reviews are thorough evaluations of all relevant studies on a specific topic, designed to reduce bias and summarize existing evidence to answer a research question. Meta-analyses, a type of systematic review, go further by statistically combining data from multiple studies to provide a more accurate estimate of an effect. Both methods follow strict protocols for selecting and analyzing studies, ensuring reliable results and uncovering insights that individual studies might miss.
These studies use mathematical models to simulate long-term costs and outcomes of healthcare interventions, particularly useful when long-term clinical trial data is unavailable. Economic modeling helps predict the future impact of treatments on healthcare systems.
Sometimes numbers only tell part of the story. Qualitative studies explore patients’ experiences, attitudes, and preferences through interviews and focus groups. By providing a human perspective, these studies add depth to the data, helping researchers understand the full impact of healthcare interventions.
How do we really know that healthcare treatments and policies work in real life, not just on paper? HEOR pharma teams strive to uncover that truth by tapping into a diverse range of real-world data (RWD) sources. These go beyond the confines of clinical trials, offering a broader, more accurate picture of how healthcare actually works in practice.
At the heart of this evidence gathering are EHRs. They are essentially a patient’s digital medical history — everything from diagnoses to treatments and outcomes is recorded here. For HEOR research, these records are invaluable for identifying trends in treatment patterns, tracking disease progression, and measuring outcomes under real-world conditions.
Claims data comes from insurance companies and includes details about healthcare services, procedures, and associated costs. HEOR uses this information to understand how healthcare resources are used, as well as the economic impact of different treatments. It’s especially helpful for evaluating cost-effectiveness and identifying utilization trends.
These are another crucial piece of the puzzle. Patient registries track groups of patients with specific conditions over time. This data helps HEOR researchers analyze long-term treatment effectiveness and health outcomes, offering insights that are critical for chronic disease management and post-market drug safety studies.
Surveys give patients a voice, capturing their experiences and perspectives on treatment effectiveness, quality of life, and satisfaction. For HEOR analysis, this data complements clinical metrics by providing a view into patient-reported outcomes , which are indispensable for understanding the full impact of healthcare interventions.
With the rise of mobile apps and wearable devices, patients are generating more health data than ever. Data from fitness trackers, medication adherence apps, and other digital tools offer HEOR researchers a window into patients’ day-to-day lives, helping to assess the true impact of treatments.
Social media platforms and online health forums are rich with patient conversations about treatments, symptoms, and support systems. HEOR can analyze this data to understand patient sentiments, concerns, and community support dynamics, offering a broader view of the patient experience.
This includes demographic and non-clinical information, such as employment records, education, and socioeconomic factors. This data provides important context by linking social determinants of health to treatment outcomes and healthcare access.
HEOR research is increasingly turning to emerging data sources like consumer behavior and geospatial data. For example, data on spending habits, housing, or environmental factors can shed light on how lifestyle and surroundings influence health outcomes. This approach offers a fuller understanding of the factors affecting patient well-being.
Of course, generating RWE isn’t without its challenges. Data can be scattered across different platforms, incomplete, or even difficult to access. That’s why collaboration between healthcare providers, insurers, and tech partners is so important. The better we get at gathering and connecting all these data points, the more meaningful and actionable the evidence becomes — helping improve healthcare decisions and, ultimately, patient lives.
ISPOR’s 2024-2025 Top 10 HEOR Trends highlights some exciting developments that show just how crucial HEOR has become in shaping healthcare decision making worldwide. Whether it’s policymakers, researchers, healthcare providers, or patients, everyone is feeling the impact of these trends.
Leading the charge, once again, is real-world evidence. No longer a supplementary concept, RWE is being integrated with randomized controlled trials to provide richer, more applicable insights that influence everything from drug efficacy assessments to regulatory approvals.
Drug pricing continues to dominate global discussions, ranking as the second major trend. In particular, the Inflation Reduction Act (IRA) in the United States has introduced landmark reforms by enabling Medicare to negotiate drug prices. While this legislation is U.S.-centric, its ripple effects could be global, as U.S. profits have historically underpinned a significant portion of pharmaceutical innovation.
Then there’s artificial intelligence. AI and machine learning have already begun revolutionizing HEOR by extracting actionable insights from vast datasets, supporting everything from predictive modeling to personalized treatment strategies.
Another notable shift is the emphasis on fostering innovation. This trend addresses the need to strike a balance between incentivizing the development of cutting-edge medical technologies and ensuring affordability for patients. Health equity follows, driven by ongoing efforts to reduce disparities in healthcare access and outcomes.
Other trends like accelerated drug approvals, value measurement, and patient centricity reflect a shared goal: speeding up access to life-saving treatments, showing measurable healthcare value, and putting patients at the center of care decisions. We’re also seeing precision medicine and public health become priorities, especially as healthcare systems adapt in a post-pandemic world.
What does all this mean for the future? Well, one thing’s clear: healthcare systems are facing mounting pressure to deliver better outcomes, and HEOR is here to provide the data that can help healthcare decision makers pave the way for a more innovative and equitable healthcare landscape.
At Viseven, we’re all about turning these trends into real-world solutions. With more than 15 years of experience in healthcare software development, we build patient portals designed to help pharma companies collect vital data while giving patients the information they deserve — clearly, compehensively, and with a user-friendly touch.
And if you want to leverage its HEOR research to craft a standout marketing campaign, our experts at Viseven have you covered too. Our content development and marketing experts (backed by our in-house medical professionals) can create highly engaging eDetailers and other custom marketing assets to hold HCPs’ attention. We’ll help you take your insights and turn them into campaigns that not only stand out but drive real impact. Just get in touch, and let’s make it happen.
Talk to our experts and explore real-world data strategies that deliver measurable outcomes.
